RVMDライブシグナル | Getagraph.comで利益を最大化

買う 105 min ago

@ $36.12

発行日: 30 4月 2024 @ 00:00

リターン: 0.69%

前回のシグナル: 4月 29 - 22:32

前回のシグナル: 売る

リターン: -0.88 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:45):
Our systems believe the stock currently is overvalued by 0.19% compare to its pairs and should correct downwards.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers...

Stats
本日の出来高	201 919
平均出来高	1.47M
時価総額	5.99B
EPS	$0 ( 2024-02-26 )
次の収益日	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.42
ATR14	$0.699 (1.92%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Goldsmith Mark A	Sell	7 500	Common Stock
2024-04-10	Goldsmith Mark A	Sell	5 000	Common Stock
2024-04-10	Goldsmith Mark A	Sell	5 000	Common Stock
2024-04-10	Patel Sushil	Sell	2 155	Stock Option (Right to Buy)
2024-04-10	Patel Sushil	Buy	2 155	Common Stock

INSIDER POWER
73.03
Last 99 transactions
Buy: 5 403 428 \| Sell: 788 601

相関 (AI algo v.1.1b): Overvalued: -0.19% $36.33 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: -0.53 (weak negative)

短: 0.33 (neutral)

Signal:(56) Neutral

Revolution Medicines Inc 相関

10 最も正の相関
TBNK	0.884
RING	0.853
RGLD	0.852
DOOO	0.849
GTH	0.834
GRAB	0.834
TRUE	0.831
PWOD	0.83
MCHI	0.828
YY	0.825

10 最も負の相関
LLNW	-0.82
SFET	-0.808
LNSR	-0.801

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Revolution Medicines Inc 相関 - 通貨/商品

0.50
( neutral )

-0.08
( neutral )

0.00
( neutral )

0.37
( neutral )

-0.83
( strong negative )

-0.70
( moderate negative )

Revolution Medicines Inc 財務諸表

Annual	2023
収益:	$11.58M
総利益:	$2.27M (19.61 %)
EPS:	$-3.86

FY	2023
収益:	$11.58M
総利益:	$2.27M (19.61 %)
EPS:	$-3.86

FY	2022
収益:	$35.38M
総利益:	$25.72M (72.71 %)
EPS:	$-3.08

FY	2021
収益:	$29.39M
総利益:	$29.39M (100.00 %)
EPS:	$-2.57

Financial Reports:

No articles found.

Revolution Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.